dentocaine 40 mg/ml + 5 micrograms/ml solution for injection
inibsa dental s.l.u., - Изпълнението на същата, комбинации - 40 mg/ml + 5 micrograms/ml solution for injection
dentocaine 40 mg/ml + 10 micrograms/ml solution for injection
inibsa dental s.l.u., - Изпълнението на същата, комбинации - 40 mg/ml + 10 micrograms/ml solution for injection
fostimon 75 iu powder and solvent for solution for injection
ibsa farmaceutici italia srl - urofollitopin - 75 iu powder and solvent for solution for injection
fostimon 150 iu powder and solvent for solution for injection
ibsa farmaceutici italia srl - 150 iu powder and solvent for solution for injection
merional 75 iu powder and solvent for solution for injection
ibsa farmaceutici italia srl - Човешки гонадотропин менопаузальный - 75 iu powder and solvent for solution for injection
merional 150 iu powder and solvent for solution for injection
ibsa farmaceutici italia srl - Човешки гонадотропин менопаузальный - 150 iu powder and solvent for solution for injection
choriomon 5000 iu powder and solvent for solution for injection
ibsa farmaceutici italia srl - 5000 iu powder and solvent for solution for injection
sarclisa
sanofi winthrop industrie - isatuximab - Множествена миелома - Антинеопластични средства - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Антинеопластични средства - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
telmisartan teva pharma
teva b.v. - Телмисартан - Хипертония - Агенти, действащи върху системата ренин-ангиотензин - Лечение на есенциална хипертония при възрастни.